Search

Your search keyword '"Asmussen, Karsten"' showing total 123 results
Start Over Author "Asmussen, Karsten"
123 results on '"Asmussen, Karsten"'

1. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors

Author

Terslev, L, primary, Ostergaard, Mikkel, additional, Georgiadis, Stylianos, additional, Brahe, Cecilie Heegaard, additional, Ellegaard, Karen, additional, Dohn, UM, additional, Fana, Viktoria, additional, Møller, Torsten, additional, Juul, Lars, additional, Huynh, Tuan Khai, additional, Krabbe, Simon, additional, Ornbjerg, L M, additional, Glinatsi, Daniel, additional, Røgind, Henrik, additional, Hansen, Annette, additional, Nørregaard, Jesper, additional, Jacobsen, Søren, additional, Jensen, Dorte V, additional, Manilo, Natalia, additional, Asmussen, Karsten, additional, Boesen, Mikael, additional, Rastiemadabadi, Zoreh, additional, Morsel-Carlsen, Lone, additional, Møller, Jakob Møllenbach, additional, Krogh, Niels Steen, additional, and Hetland, Merete Lund, additional

Published
2022
Full Text
View/download PDF

2. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care:characteristics and predictors

Author

Terslev, L., Ostergaard, Mikkel, Georgiadis, Stylianos, Brahe, Cecilie Heegaard, Ellegaard, Karen, Dohn, U. M., Fana, Viktoria, Møller, Torsten, Juul, Lars, Huynh, Tuan Khai, Krabbe, Simon, Ornbjerg, L. M., Glinatsi, Daniel, Røgind, Henrik, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Jensen, Dorte V., Manilo, Natalia, Asmussen, Karsten, Boesen, Mikael, Rastiemadabadi, Zoreh, Morsel-Carlsen, Lone, Møller, Jakob Møllenbach, Krogh, Niels Steen, Hetland, Merete Lund, Terslev, L., Ostergaard, Mikkel, Georgiadis, Stylianos, Brahe, Cecilie Heegaard, Ellegaard, Karen, Dohn, U. M., Fana, Viktoria, Møller, Torsten, Juul, Lars, Huynh, Tuan Khai, Krabbe, Simon, Ornbjerg, L. M., Glinatsi, Daniel, Røgind, Henrik, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Jensen, Dorte V., Manilo, Natalia, Asmussen, Karsten, Boesen, Mikael, Rastiemadabadi, Zoreh, Morsel-Carlsen, Lone, Møller, Jakob Møllenbach, Krogh, Niels Steen, and Hetland, Merete Lund

Abstract

OBJECTIVE: To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards withdrawal of biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: Sustained clinical remission was defined as Disease Activity Score for 28 joints (DAS28)-C reactive protein (CRP) ≤2.6 without radiographic progression for >1 year. bDMARDs were tapered according to a mandatory clinical guideline to two-thirds of standard dose at baseline, half of dose at week 16 and discontinuation at week 32. Prospective assessments for 2 years included clinical evaluation, conventional radiography, ultrasound and MRI for signs of inflammation and bone changes. Flare was defined as DAS28-CRP ≥2.6 with ∆DAS28-CRP ≥1.2 from baseline. Baseline predictors of flare were assessed by logistic regression analyses. RESULTS: Of 142 included patients, 121 (85%) flared during follow-up of which 86% regained remission within 24 weeks after flare. Patients that flared were more often rheumatoid factor positive, had tried more bDMARDs and had higher baseline ultrasound synovitis sum scores than those not flaring. For patients on standard dose, predictors of flare within 16 weeks after reduction to two-thirds of standard dose were baseline MRI-osteitis (OR 1.16; 95% CI 1.03 to 1.33; p=0.014), gender (female) (OR 6.71; 95% CI 1.68 to 46.12; p=0.005) and disease duration (OR 1.06; 95% CI 1.01 to 1.11; p=0.020). Baseline predictors for flare within 2 years were ultrasound grey scale synovitis sum score (OR 1.19; 95% CI 1.02 to 1.44; p=0.020) and number of previous bDMARDs (OR 4.07; 95% CI 1.35 to 24.72; p=0.007). CONCLUSION: The majority of real-world patients with RA tapering bDMARDs flared during tapering, with the majority regaining remission after stepwise dose increase. Demographic and imaging parameters (MR-osteitis/ultrasound greyscale synovitis) were independent predictors of immediate flare and flare overall

Published
2022

4. Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods

Author

Pedersen, Susanne J., Poddubnyy, Denis, Srensen, Inge J., Loft, Anne-Gitte, Hindrup, Jens S., Thamsborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nrregaard, Jesper, Piil, Anne-Dorthe, Mller, Jakob M., Jurik, Anne-Grethe, Balding, Lone, Lambert, Robert G., Sieper, Joachim, and stergaard, Mikkel

Published
2016
Full Text
View/download PDF

5. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission

Author

Terslev, Lene, Brahe, Cecilie Heegaard, Hetland, Merete Lund, Georgiadis, Stylianos, Ellegaard, Karen, Juul, Lars, Huynh, Tuan, Døhn, Uffe Møller, Fana, Viktoria, Møller, Torsten, Krabbe, Simon, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Røgind, Henrik, Hansen, Anette, Nørregaard, Jesper, Jacobsen, Søren, Jensen, Dorte Vendelbo, Manilo, Natalia, Asmussen, Karsten, Boesen, Mikael, Rastiemadabadi, Zoreh, Morsel-Carlsen, Lone, Møller, Jakob Møllenbach, Krogh, Niels Steen, Østergaard, Mikkel, Terslev, Lene, Brahe, Cecilie Heegaard, Hetland, Merete Lund, Georgiadis, Stylianos, Ellegaard, Karen, Juul, Lars, Huynh, Tuan, Døhn, Uffe Møller, Fana, Viktoria, Møller, Torsten, Krabbe, Simon, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Røgind, Henrik, Hansen, Anette, Nørregaard, Jesper, Jacobsen, Søren, Jensen, Dorte Vendelbo, Manilo, Natalia, Asmussen, Karsten, Boesen, Mikael, Rastiemadabadi, Zoreh, Morsel-Carlsen, Lone, Møller, Jakob Møllenbach, Krogh, Niels Steen, and Østergaard, Mikkel

Abstract

Objective: To assess the ability of ultrasound to predict successful tapering and successful discontinuation of biological DMARDs (bDMARDs) at the 2-year follow-up in RA patients in sustained remission. Methods: Patients in sustained remission (DAS28-CRP ≤ 2.6) and with no radiographic progression the previous year tapered bDMARDs according to a standardized regime. A total of 119 of these patients were included in this ultrasound substudy. At baseline, clinical assessment, MRI, X-ray and ultrasound of 24 joints were performed. Ultrasound-detected synovitis was defined and scored 0-3 using the OMERACT scoring system at the joint level for both grey-scale and Doppler activity. Sum scores for each ultrasound modality were calculated for 24 joints at the patient level. The final state of treatment was assessed after 2 years. The predictive value of ultrasound measures for successful tapering and discontinuation at the 2-year follow-up was assessed via logistic regression analyses. Results: Negative IgM-RF [odds ratio (OR) = 0.29, 95% CI: 0.10-0.85; P = 0.024] and lower Doppler sum score of 24 joints (OR = 0.44, 95% CI: 0.15, 0.87; P = 0.014) were independent predictors for successful discontinuation of bDMARDs at the 2-year follow-up. The predictive value of the Doppler sum score was independent of MRI findings. Previous numbers of bDMARDs were predictive of successful tapering (OR = 0.58, 95% CI: 0.35, 0.91; P = 0.018), whereas ultrasound was not. Clinical parameters were not predictive of successful tapering/discontinuation. Conclusion: Doppler sum score was an independent predictor for successful discontinuation of bDMARDs at the 2-year follow-up - the odds for achieving successful discontinuation decreased by 56% per one-unit increase in Doppler sum score. Ultrasound could not predict successful tapering.

Published
2021

6. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

Author

Møller-Bisgaard, Signe, Georgiadis, Stylianos, Hørslev-Petersen, Kim, Ejbjerg, Bo, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Møller, Jakob, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete H., Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik S., Østergaard, Mikkel, Møller-Bisgaard, Signe, Georgiadis, Stylianos, Hørslev-Petersen, Kim, Ejbjerg, Bo, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Møller, Jakob, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete H., Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik S., and Østergaard, Mikkel

Abstract

OBJECTIVES: To study if clinical, radiographic and MRI markers can predict MRI and radiographic damage progression and achievement of stringent remission in patients with established RA in clinical remission followed by a targeted treatment strategy. METHODS: RA patients (DAS28-CRP <3.2, no swollen joints) receiving conventional synthetic DMARDs were randomized to conventional or MRI-targeted treat-to-target strategies with predefined algorithmic treatment escalations. Potentially predictive baseline variables were tested in multivariate logistic regression analyses. RESULTS: In the 171 patients included, baseline MRI osteitis independently predicted progression in MRI erosion [odds ratio (OR) 1.13 (95% CI 1.06, 1.22)], joint space narrowing [OR 1.15 (95% CI 1.07, 1.24)] and combined damage [OR 1.23 (95% CI 1.13, 1.37)], while tenosynovitis independently predicted MRI erosion progression [OR 1.13 (95% CI 1.03, 1.25)]. A predictor of radiographic erosion progression was age, while gender predicted progression in joint space narrowing. Following an MRI treat-to-target strategy predicted stringent remission across all remission definitions: Clinical Disease Activity Index remission OR 2.94 (95% CI 1.25, 7.52), Simplified Disease Activity Index remission OR 2.50 (95% CI 1.01, 6.66), ACR/EULAR Boolean remission OR 5.47 (95% CI 2.33, 14.13). Similarly, low tender joint count and low patient visual analogue scale pain and global independently predicted achievement of more stringent remission. CONCLUSION: Baseline MRI osteitis and tenosynovitis were independent predictors of 2 year MRI damage progression in RA patients in clinical remission, while independent predictors of radiographic damage progression were age and gender. Following an MRI treat-to-target strategy, low scores of patient-reported outcomes and low tender joint count predicted achievement of stringent remission. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT01656278.

Published
2021

7. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission

Author

Terslev, Lene, primary, Brahe, Cecilie Heegaard, additional, Hetland, Merete Lund, additional, Georgiadis, Stylianos, additional, Ellegaard, Karen, additional, Juul, Lars, additional, Huynh, Tuan, additional, Døhn, Uffe Møller, additional, Fana, Viktoria, additional, Møller, Torsten , additional, Krabbe, Simon, additional, Ørnbjerg, Lykke Midtbøll, additional, Glinatsi, Daniel, additional, Røgind, Henrik, additional, Hansen, Anette, additional, Nørregaard, Jesper, additional, Jacobsen, Søren, additional, Jensen, Dorte Vendelbo, additional, Manilo, Natalia , additional, Asmussen, Karsten, additional, Boesen, Mikael, additional, Rastiemadabadi, Zoreh, additional, Morsel-Carlsen, Lone , additional, Møller, Jakob Møllenbach, additional, Krogh, Niels Steen, additional, and Østergaard, Mikkel , additional

Published
2021
Full Text
View/download PDF

8. Radiographic Progression Is Associated With Resolution of Systemic Inflammation in Patients With Axial Spondylarthritis Treated With Tumor Necrosis Factor α Inhibitors: a Study of Radiographic Progression, Inflammation on Magnetic Resonance Imaging, and Circulating Biomarkers of Inflammation, Angiogenesis, and Cartilage and Bone Turnover

Author

Pedersen, Susanne Juhl, Srensen, Inge Juul, Lambert, Robert G. W., Hermann, Kay-Geert A., Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Hansen, Annette, Hansen, Michael Sejer, Thamsborg, Gorm, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten H., Jurik, Anne Grethe, Mller, Jakob, Hasselquist, Maria, Mikkelsen, Dorrit, and stergaard, Mikkel

Published
2011
Full Text
View/download PDF

9. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Tvede, Niels, Hansen, Michael Sejer, Thamsborg, Gorm, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Jurik, Anne Grethe, Møller, Jakob, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Lambert, Robert, Hansen, Annette, and Østergaard, Mikkel

Published
2011
Full Text
View/download PDF

10. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission

Author

Møller-Bisgaard, Signe, primary, Georgiadis, Stylianos, additional, Hørslev-Petersen, Kim, additional, Ejbjerg, Bo, additional, Hetland, Merete Lund, additional, Ørnbjerg, Lykke Midtbøll, additional, Glinatsi, Daniel, additional, Møller, Jakob, additional, Boesen, Mikael, additional, Stengaard-Pedersen, Kristian, additional, Madsen, Ole Rintek, additional, Jensen, Bente, additional, Villadsen, Jan Alexander, additional, Hauge, Ellen-Margrethe, additional, Bennett, Philip, additional, Hendricks, Oliver, additional, Asmussen, Karsten, additional, Kowalski, Marcin, additional, Lindegaard, Hanne, additional, Bliddal, Henning, additional, Krogh, Niels Steen, additional, Ellingsen, Torkell, additional, Nielsen, Agnete H., additional, Balding, Lone, additional, Jurik, Anne Grethe, additional, Thomsen, Henrik S., additional, and Østergaard, Mikkel, additional

Published
2020
Full Text
View/download PDF

11. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor α inhibitors

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hermann, Kay-Geert A, Madsen, Ole Rintek, Tvede, Niels, Hansen, Michael Sejer, Thamsborg, Gorm, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Johansen, Julia S, Jurik, Anne Grethe, Møller, Jakob, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Hansen, Annette, and Østergaard, Mikkel

Published
2010
Full Text
View/download PDF

12. MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION

Author

Møller-bisgaard, Signe, Hørslev-petersen, Kim, Ejbjerg, Bo, Hetland, Merete L., Ørnbjerg, Lykke, Glinatsi, Daniel, Møller, Jakob Møllenbach, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole, Jensen, Bente, Villadsen, Jan, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne Merete, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete, Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik, Østergaard, Mikkel, Møller-bisgaard, Signe, Hørslev-petersen, Kim, Ejbjerg, Bo, Hetland, Merete L., Ørnbjerg, Lykke, Glinatsi, Daniel, Møller, Jakob Møllenbach, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole, Jensen, Bente, Villadsen, Jan, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne Merete, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete, Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik, and Østergaard, Mikkel

Published
2019

13. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis:The IMAGINE-RA randomized clinical trial

Author

Møller-Bisgaard, Signe, Hørslev-Petersen, Kim, Ejbjerg, Bo, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Møller, Jakob, Boesen, Mikael, Christensen, Robin, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne, Nielsen, Sabrina Mai, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete H., Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik S., Østergaard, Mikkel, Møller-Bisgaard, Signe, Hørslev-Petersen, Kim, Ejbjerg, Bo, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Glinatsi, Daniel, Møller, Jakob, Boesen, Mikael, Christensen, Robin, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin, Lindegaard, Hanne, Nielsen, Sabrina Mai, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell, Nielsen, Agnete H., Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik S., and Østergaard, Mikkel

Abstract

IMPORTANCE Whether using magnetic resonance imaging (MRI) to guide treatment in patients with rheumatoid arthritis (RA) improves disease activity and slows joint damage progression is unknown. OBJECTIVE To determine whether an MRI-guided treat-to-target strategy vs a conventional clinical treat-to-target strategy improves outcomes in patients with RA in clinical remission. DESIGN, SETTING, AND PARTICIPANTS Two-year, randomized, multicenter trial conducted at 9 hospitals in Denmark. Two hundred patients with RA in clinical remission (disease activity score in 28 joints-C-reactive protein [DAS28-CRP] <3.2 and no swollen joints) were enrolled between April 2012 and June 2015. The final follow-up visit was April 2017. INTERVENTIONS Patients were randomly allocated (1:1) to an MRI-guided vs a conventional treat-to-target strategy. In the MRI-guided group, the treatment goal was absence of MRI bone marrow edema combined with clinical remission, defined as DAS28-CRP of 3.2 or less and no swollen joints. In the conventional group, the treatment goal was clinical remission. MAIN OUTCOMES AND MEASURES Co-primary outcomeswere proportions of patients achieving DAS28-CRP remission (DAS28-CRP <2.6) and with no radiographic progression (no increase in total van der Heijde-modified Sharp score) at 24 months. Significance testing for the primary outcome was based on 1-sided testing. Secondary outcomes were clinical and MRI measures of disease activity, physical function, and quality of life. RESULTS Of 200 patients randomized (133 women [67%]; mean [SD] age, 61.6 [10.5] years; median baseline DAS28-CRP, 1.9 [interquartile range, 1.7-2.2]; van der Heijde-modified Sharp score, 18.0 [interquartile range, 7.0-42.5]), 76 patients (76%) in the MRI-guided group and 95 (95%) in the conventional group completed the study. Of these, 64 (85%) vs 83 (88%), respectively, reached the primary clinical end point (risk difference, -4.8%[1-sided 95%CI, -13.6%to + ∞; 1-sided P = .19]) and 49

Published
2019

14. Sjögrens syndrom

Author

Voss, Anne, Heller Asmussen, Karsten, Voss, Anne, Manniche, Claus, Mašić, Dženan, Hauge, Ellen-Margrethe, and Johannsen, Finn Elkjær

Published
2018

15. The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission:Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial

Author

Møller-Bisgaard, Signe, Hørslev-Petersen, Kim, Ejbjerg, Bo Jannik, Lund Hetland, Merete, Glinatsi, Daniel, Ørnbjerg, Lykke Midtbøll, Møller, Jakob M, Boesen, Mikael, Christensen, Robin, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Bennett, Philip, Hendricks, Oliver, Asmussen, Karsten, Kowalski, Marcin Ryszard, Lindegaard, Hanne Merete, Mai Nielsen, Sabrina, Bliddal, Henning, Krogh, Niels Steen, Ellingsen, Torkell Juulsgaard, Nielsen, Agente, Balding, Lone, Jurik, Anne Grethe, Thomsen, Henrik S., and Østergaard, Mikkel

Published
2018

16. OP0331 MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION

Author

Møller-Bisgaard, Signe, primary, Hørslev-Petersen, Kim, additional, Ejbjerg, Bo, additional, Hetland, Merete L., additional, Ørnbjerg, Lykke, additional, Glinatsi, Daniel, additional, Møller, Jakob Møllenbach, additional, Boesen, Mikael, additional, Stengaard-Pedersen, Kristian, additional, Madsen, Ole, additional, Jensen, Bente, additional, Villadsen, Jan, additional, Hauge, Ellen Margrethe, additional, Bennett, Philip, additional, Hendricks, Oliver, additional, Asmussen, Karsten, additional, Kowalski, Marcin, additional, Lindegaard, Hanne Merete, additional, Bliddal, Henning, additional, Krogh, Niels Steen, additional, Ellingsen, Torkell, additional, Nielsen, Agnete, additional, Balding, Lone, additional, Jurik, Anne Grethe, additional, Thomsen, Henrik, additional, and Ǿstergaard, Mikkel, additional

Published
2019
Full Text
View/download PDF

17. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis

Author

Møller-Bisgaard, Signe, primary, Hørslev-Petersen, Kim, additional, Ejbjerg, Bo, additional, Hetland, Merete Lund, additional, Ørnbjerg, Lykke Midtbøll, additional, Glinatsi, Daniel, additional, Møller, Jakob, additional, Boesen, Mikael, additional, Christensen, Robin, additional, Stengaard-Pedersen, Kristian, additional, Madsen, Ole Rintek, additional, Jensen, Bente, additional, Villadsen, Jan Alexander, additional, Hauge, Ellen-Margrethe, additional, Bennett, Philip, additional, Hendricks, Oliver, additional, Asmussen, Karsten, additional, Kowalski, Marcin, additional, Lindegaard, Hanne, additional, Nielsen, Sabrina Mai, additional, Bliddal, Henning, additional, Krogh, Niels Steen, additional, Ellingsen, Torkell, additional, Nielsen, Agnete H., additional, Balding, Lone, additional, Jurik, Anne Grethe, additional, Thomsen, Henrik S., additional, and Østergaard, Mikkel, additional

Published
2019
Full Text
View/download PDF

19. Development and Validation of MRI Sacroiliac Joint Scoring Methods for the Semiaxial Scan Plane Corresponding to the Berlin and SPARCC MRI Scoring Methods, and of a New Global MRI Sacroiliac Joint Method

Author

Hededal, Pernille, Østergaard, Mikkel, Sørensen, Inge Juul, Loft, Anne Gitte, Hindrup, Jens S, Thamsborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Møller, Jakob M, Jurik, Anne Grethe, Morsel, Lone, Balding, Lone, Pedersen, Susanne Juhl, Hededal, Pernille, Østergaard, Mikkel, Sørensen, Inge Juul, Loft, Anne Gitte, Hindrup, Jens S, Thamsborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Møller, Jakob M, Jurik, Anne Grethe, Morsel, Lone, Balding, Lone, and Pedersen, Susanne Juhl

Abstract

OBJECTIVE: To develop semiaxial magnetic resonance imaging (MRI) scoring methods for assessment of sacroiliac joint (SIJ) bone marrow edema (BME) in patients with axial spondyloarthritis, and to compare the reliability with equivalent semicoronal scoring methods.METHODS: Two semiaxial SIJ MRI scoring methods were developed based on the principles of the semicoronal Berlin and Spondyloarthritis Research Consortium of Canada (SPARCC) methods. A global quadrant-based method was also developed. Baseline and 12-week MRI of the SIJ from 51 patients participating in a randomized double-blind placebo-controlled trial of adalimumab 40 mg every other week versus placebo were scored by the semiaxial and the corresponding semicoronal methods. Results were compared by linear regression analysis. The reproducibility and sensitivity were evaluated by intraclass correlation coefficients (ICC) and smallest detectable change [SDC, absolute values and percentage of the highest observed score (SDC-HOS)].RESULTS: Interreader and intrareader ICC were moderate to very high for semiaxial scoring methods (baseline 0.83-0.88 and 0.85-0.97; change 0.33-0.78), while high to very high for semicoronal scoring methods (baseline 0.90-0.92 and 0.93-0.97; change 0.77-0.89). Association between semiaxial and semicoronal scores were high for both the Berlin and SPARCC method (baseline: R2 = 0.93 and 0.88; change: R2 = 0.82 and 0.87, respectively), while lower for the global method (baseline: R2 = 0.79; change: R2 = 0.54). The SDC-HOS were 9.8-18.6% and 5.9-10.7% for the semiaxial and semicoronal methods, respectively.CONCLUSION: Detection of SIJ BME in the semiaxial scan plane is feasible and reproducible. However, a slightly lower reliability of all 3 semiaxial methods supports the general practice of using the coronal scan-plane in therapeutic studies.

Published
2018

20. Whole-body magnetic resonance imaging in axial spondyloarthritis:Reduction of sacroiliac, spinal, and entheseal inflammation in a placebo-controlled trial of adalimumab

Author

Krabbe, Simon, Østergaard, Mikkel, Eshed, Iris, Sørensen, Inge J., Jensen, Bente, Møller, Jakob M., Balding, Lone, Madsen, Ole R., Asmussen, Karsten, Eng, Grith, Jørgensen, Niklas R., Pedersen, Susanne J., Krabbe, Simon, Østergaard, Mikkel, Eshed, Iris, Sørensen, Inge J., Jensen, Bente, Møller, Jakob M., Balding, Lone, Madsen, Ole R., Asmussen, Karsten, Eng, Grith, Jørgensen, Niklas R., and Pedersen, Susanne J.

Abstract

Objective. To investigate whether adalimumab (ADA) reduces whole-body (WB-) magnetic resonance imaging (MRI) indices for inflammation in the entheses, peripheral joints, sacroiliac joints, spine, and the entire body in patients with axial spondyloarthritis (axSpA). Methods. An investigator-initiated, randomized, placebo-controlled, double-blinded 48-week followup trial included 49 patients with axSpA, who had Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4.0 despite treatment with nonsteroidal antiinflammatory drugs and a clinical indication for tumor necrosis factor inhibitor treatment. Patients were randomized to subcutaneous ADA 40 mg or placebo every other week for 6 weeks; thereafter, all patients received ADA. Conventional MRI and WBMRI were performed at weeks 0, 6, 24, and 48. The primary WBMRI endpoint was the proportion of patients with an improvement in WBMRI total inflammation index above the smallest detectable change (SDC) at Week 6. Results. The primary WBMRI endpoint (improvement of SDC > 2.3) was met in 11 (44%) patients in the ADA group and 3 (13%) patients in the placebo group (p = 0.025, Fisher’s exact test). The primary conventional MRI endpoint, the minimally important change in Spondyloarthritis Research Consortium of Canada Spine MRI Inflammation Index at Week 6, was achieved by 9 (36%) patients in the ADA group and 4 (17%) patients in the placebo group (p = 0.20). The primary clinical endpoint, BASDAI reduction > 50% or 2.0 at Week 24, was attained by 32 (65%) patients. Conclusion. ADA provided significant reductions in WBMRI indices of peripheral, axial, and whole-body inflammation in patients with axSpA. WBMRI is promising for objective assessment and monitoring of peripheral and axial disease activity in future clinical trials.

Published
2018

21. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors

Author

Brahe, Cecilie Heegaard, primary, Krabbe, Simon, additional, Østergaard, Mikkel, additional, Ørnbjerg, Lykke, additional, Glinatsi, Daniel, additional, Røgind, Henrik, additional, Jensen, Hanne S, additional, Hansen, Annette, additional, Nørregaard, Jesper, additional, Jacobsen, Søren, additional, Terslev, Lene, additional, Huynh, Tuan K, additional, Jensen, Dorte V, additional, Manilo, Natalia, additional, Asmussen, Karsten, additional, Brown Frandsen, Per, additional, Boesen, Mikael, additional, Rastiemadabadi, Zoreh, additional, Morsel Carlsen, Lone, additional, Møller, Jakob M, additional, Krogh, Niels S, additional, and Hetland, Merete Lund, additional

Published
2018
Full Text
View/download PDF

22. Whole-body Magnetic Resonance Imaging in Axial Spondyloarthritis: Reduction of Sacroiliac, Spinal, and Entheseal Inflammation in a Placebo-controlled Trial of Adalimumab

Author

Krabbe, Simon, primary, Østergaard, Mikkel, additional, Eshed, Iris, additional, Sørensen, Inge J., additional, Jensen, Bente, additional, Møller, Jakob M., additional, Balding, Lone, additional, Madsen, Ole R., additional, Asmussen, Karsten, additional, Eng, Grith, additional, Jørgensen, Niklas R., additional, and Pedersen, Susanne J., additional

Published
2018
Full Text
View/download PDF

23. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis:a systematic review meta-analysis

Author

Tarp, Simon, Eric Furst, Daniel, Boers, Maarten, Luta, George, Bliddal, Henning, Tarp, Ulrik, Heller Asmussen, Karsten, Brock, Birgitte, Dossing, Anna, Schjødt Jørgensen, Tanja, Thirstrup, Steffen, Christensen, Robin, Tarp, Simon, Eric Furst, Daniel, Boers, Maarten, Luta, George, Bliddal, Henning, Tarp, Ulrik, Heller Asmussen, Karsten, Brock, Birgitte, Dossing, Anna, Schjødt Jørgensen, Tanja, Thirstrup, Steffen, and Christensen, Robin

Abstract

Objectives.: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA.Methods.: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i.e. no b/ts-DMARD treatment), based on subjects experiencing an event in relation to person-years. Confidence in the estimates was assessed by applying the Grading of Recommendations Assessment, Development and Evaluation approach (GRADE).Results.: A total of 117 trials (47 615 patients) were included. SAEs were more common with certolizumab compared with abatacept (rate ratio = 1.58, 95% CI: 1.18, 2.14), adalimumab (1.36, 95% CI: 1.02, 1.81), etanercept (1.60, 95% CI: 1.18, 2.17), golimumab (1.45, 95% CI: 1.00, 2.08), rituximab (1.63, 95% CI: 1.16, 2.30), tofacitinib (1.44, 95% CI: 1.03, 2.02) and control (1.45, 95% CI: 1.13, 1.87); and tocilizumab compared with abatacept (1.30, 95% CI: 1.03, 1.65), etanercept (1.31, 95% CI: 1.04, 1.67) and rituximab (1.34, 95% CI: 1.01, 1.78). No other comparisons were statistically significant. Accounting for study duration confirmed our findings for up to 6 months' treatment but not for longer-term treatment (6-24 months). No differences in mortality between b/ts-DMARDs and control were found. Based on the GRADE approach, confidence in the estimates was low due to lack of head-to-head comparison trials and imprecision in indirect estimates.Conclusion.: Despite low confidence in the estimates, our analysis found potential differences in rates of SAEs. Our data suggest caution should be taken when deciding among available drugs.Systematic review registration number.: PROSPERO

Published
2017

24. Development and Validation of MRI Sacroiliac Joint Scoring Methods for the Semiaxial Scan Plane Corresponding to the Berlin and SPARCC MRI Scoring Methods, and of a New Global MRI Sacroiliac Joint Method

Author

Hededal, Pernille, primary, Østergaard, Mikkel, additional, Sørensen, Inge Juul, additional, Loft, Anne Gitte, additional, Hindrup, Jens S., additional, Thamsborg, Gorm, additional, Asmussen, Karsten, additional, Hendricks, Oliver, additional, Nørregaard, Jesper, additional, Møller, Jakob M., additional, Jurik, Anne Grethe, additional, Morsel, Lone, additional, Balding, Lone, additional, and Pedersen, Susanne Juhl, additional

Published
2017
Full Text
View/download PDF

25. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors.

Author

Brahe, Cecilie Heegaard, Krabbe, Simon, Østergaard, Mikkel, Ørnbjerg, Lykke, Glinatsi, Daniel, Røgind, Henrik, Jensen, Hanne S, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Terslev, Lene, Huynh, Tuan K, Jensen, Dorte V, Manilo, Natalia, Asmussen, Karsten, Frandsen, Per Brown, Boesen, Mikael, Rastiemadabadi, Zoreh, Carlsen, Lone Morsel, and Møller, Jakob M

Subjects
RHEUMATOID arthritis diagnosis, RHEUMATOID arthritis treatment, ANTIRHEUMATIC agents, BIOTHERAPY, COMPUTED tomography, MAGNETIC resonance imaging, MEDICAL protocols, SEX distribution, TERMINATION of treatment, TUMOR necrosis factors, TREATMENT effectiveness, DISEASE remission, TREATMENT duration, CHEMICAL inhibitors, THERAPEUTICS
Abstract

Objectives A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation. Methods One-hundred-and-forty-three patients (91% receiving TNF inhibitor and 9% a non-TNF inhibitor) with sustained disease activity score (DAS28-CRP)⩽2.6 and no radiographic progression the previous year were included. bDMARD was reduced to two-thirds of standard dose at baseline, half after 16 weeks, and discontinued after 32 weeks. Patients who flared (defined as either DAS28-CRP ⩾ 2.6 and ΔDAS28-CRP ⩾ 1.2 from baseline, or erosive progression on X-ray and/or MRI) stopped tapering and were escalated to the previous dose level. Results One-hundred-and-forty-one patients completed 2-year follow-up. At 2 years, 87 patients (62%) had successfully tapered bDMARDs, with 26 (18%) receiving two-thirds of standard dose, 39 (28%) half dose and 22 (16%) having discontinued; and 54 patients (38%) were receiving full dose. ΔDAS28-CRP0-2yrs was 0.1((−0.2)-0.4) (median (interquartile range)) and mean ΔTotal-Sharp-Score0-2yrs was 0.01(1.15)(mean(s. d.)). Radiographic progression was observed in nine patients (7%). Successful tapering was independently predicted by: ⩽1 previous bDMARD, male gender, low baseline MRI combined inflammation score or combined damage score. Negative IgM-RF predicted successful discontinuation. Conclusion By implementing a clinical guideline, 62% of RA patients in sustained remission in routine care were successfully tapered, including 16% successfully discontinued at 2 years. Radiographic progression was rare. Maximum one bDMARDs, male gender, and low baseline MRI combined inflammation and combined damage scores were independent predictors for successful tapering. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. Development and Validation of Berlin and Sparcc MRI Sacroiliac Joint Scoring Methods for the Semi-Axial Scan Plan

Author

Hededal, Pernille, Østergaard, Mikkel, Sorensen, Inge Juul, Loft, Anne Gitte, Hindrup, Jens, Thamborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Møller, Jakob M, Jurik, Anne Grethe, Morsel-Carlsen, Lone, Balding, Lone, Pedersen, Susanne Juhl, Hededal, Pernille, Østergaard, Mikkel, Sorensen, Inge Juul, Loft, Anne Gitte, Hindrup, Jens, Thamborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Møller, Jakob M, Jurik, Anne Grethe, Morsel-Carlsen, Lone, Balding, Lone, and Pedersen, Susanne Juhl

Published
2016

27. Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission:1-Year Results of a Guideline-Directed Longitudinal Cohort Study

Author

Brahe, Cecilie Heegaard, Krabbe, Simon, Østergaard, Mikkel, Henrik Rogind, Henrik, Jensen, Hanne Slott, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Terslev, Lene, Huynh, Tuan Khai, Jensen, Dorte Vendelbo, Manilo, Natalia, Asmussen, Karsten Heller, Brown-Frandsen, Per, Boesen, Mikael, Rastiemadabadi, Zoreh, Glinatsi, Daniel, Morsel-Carlsen, Lone, Møller, Jakob M, Krogh, Niels Steen, Hetland, Merete Lund, Brahe, Cecilie Heegaard, Krabbe, Simon, Østergaard, Mikkel, Henrik Rogind, Henrik, Jensen, Hanne Slott, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Terslev, Lene, Huynh, Tuan Khai, Jensen, Dorte Vendelbo, Manilo, Natalia, Asmussen, Karsten Heller, Brown-Frandsen, Per, Boesen, Mikael, Rastiemadabadi, Zoreh, Glinatsi, Daniel, Morsel-Carlsen, Lone, Møller, Jakob M, Krogh, Niels Steen, and Hetland, Merete Lund

Published
2016

28. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods

Author

Pedersen, Susanne Juhl, Poddubnyy, Denis, Sørensen, Inge J, Loft, Anne Gitte, Hindrup, Jens S, Thamsborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Piil, Anne-Dorthe, Møller, Jakob M, Jurik, Anne-Grethe, Balding, Lone, Lambert, Robert G., Sieper, Joachim, Østergaard, Mikkel, Pedersen, Susanne Juhl, Poddubnyy, Denis, Sørensen, Inge J, Loft, Anne Gitte, Hindrup, Jens S, Thamsborg, Gorm, Asmussen, Karsten, Hendricks, Oliver, Nørregaard, Jesper, Piil, Anne-Dorthe, Møller, Jakob M, Jurik, Anne-Grethe, Balding, Lone, Lambert, Robert G., Sieper, Joachim, and Østergaard, Mikkel

Abstract

OBJECTIVE: To investigate changes in magnetic resonance imaging (MRI)-assessed inflammation and structural lesions in the sacroiliac (SI) joints during treatment with adalimumab versus placebo.METHODS: In a 48-week double-blind, placebo-controlled trial, 52 patients with spondyloarthritis were randomized to receive subcutaneous injections of either adalimumab 40 mg (n = 25) or placebo (n = 27) every other week for 12 weeks. Patients in the adalimumab group continued to receive and patients in the placebo group were switched to adalimumab 40 mg every other week for an additional 12 weeks. MRI of the SI joints was performed at weeks 0, 12, 24, and 48, and the images were assessed independently in a blinded manner using the modified Berlin and the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores for inflammation and structural lesions of the SI joints.RESULTS: At baseline, 56% of the adalimumab group and ∼72% of the placebo group had an MRI-assessed inflammation score of ≥1. Among the patients with inflammation at baseline, the mean percent reductions in MRI scores for inflammation from week 0 to 12 were greater in the adalimumab group compared with the placebo group (Berlin method, -62% versus -5%; SPARCC method, -58% versus -12% [both P < 0.04]). Furthermore, the mean SPARCC erosion score decreased (-0.6) and the SPARCC backfill score increased (+0.8) in the adalimumab group from week 0 to week 12. From week 12 to week 24, larger absolute reductions in the Berlin/SPARCC inflammation scores and the SPARCC erosion score and larger increases in the Berlin/SPARCC fatty lesion scores were seen in the placebo group compared with the adalimumab group. In univariate regression analyses (analysis of covariance) and multivariate stepwise regression analyses, treatment with adalimumab was independently associated with regression of the SPARCC erosion score from week 0 to 12 but not with changes in the other types of MRI lesions.CONC

Published
2016

29. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis

Author

Tarp, Simon, primary, Eric Furst, Daniel, additional, Boers, Maarten, additional, Luta, George, additional, Bliddal, Henning, additional, Tarp, Ulrik, additional, Heller Asmussen, Karsten, additional, Brock, Birgitte, additional, Dossing, Anna, additional, Schjødt Jørgensen, Tanja, additional, Thirstrup, Steffen, additional, and Christensen, Robin, additional

Published
2016
Full Text
View/download PDF

30. EULAR Sjögren's syndrome disease activity index (ESSDAI) : a user guide

Author

Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, Vollenweider, Cristina, Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, and Vollenweider, Cristina

Published
2015

31. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide

Author

MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, Infection & Immunity, Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, Vollenweider, Cristina, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, Infection & Immunity, Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, and Vollenweider, Cristina

Published
2015

32. EULAR Sjögren's syndrome disease activity index (ESSDAI):a user guide

Author

Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, Vollenweider, Cristina, Seror, Raphaèle, Bowman, Simon J, Brito-Zeron, Pilar, Theander, Elke, Bootsma, Hendrika, Tzioufas, Athanasios, Gottenberg, Jacques-Eric, Ramos-Casals, Manel, Dörner, Thomas, Ravaud, Philippe, Vitali, Claudio, Mariette, Xavier, Asmussen, Karsten, Jacobsen, Soren, Bartoloni, Elena, Gerli, Roberto, Bijlsma, Johannes Wj, Kruize, Aike A, Bombardieri, Stefano, Bookman, Arthur, Kallenberg, Cees, Meiners, Petra, Brun, Johan G, Jonsson, Roland, Caporali, Roberto, Carsons, Steven, De Vita, Salvatore, Del Papa, Nicoletta, Devauchelle, Valerie, Saraux, Alain, Fauchais, Anne-Laure, Sibilia, Jean, Hachulla, Eric, Illei, Gabor, Isenberg, David, Jones, Adrian, Manoussakis, Menelaos, Mandl, Thomas, Jacobsson, Lennart, Demoulins, Frederic, Montecucco, Carlomaurizio, Ng, Wan-Fai, Nishiyama, Sumusu, Omdal, Roald, Parke, Ann, Praprotnik, Sonja, Tomsic, Matjia, Price, Elizabeth, Scofield, Hal, L Sivils, Kathy, Smolen, Josef, Laqué, Roser Solans, Steinfeld, Serge, Sutcliffe, Nurhan, Sumida, Takayuki, Valesini, Guido, Valim, Valeria, Vivino, Frederick B, and Vollenweider, Cristina

Abstract

The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use of the ESSDAI, some domains appear to be more challenging to rate than others. The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure, even a primary outcome measure, in current randomised clinical trials. Therefore, ensuring an accurate and reproducible rating of each domain, by providing a more detailed definition of each domain, has emerged as an urgent need. The purpose of the present article is to provide a user guide for the ESSDAI. This guide provides definitions and precisions on the rating of each domain. It also includes some minor improvement of the score to integrate advance in knowledge of disease manifestations. This user guide may help clinicians to use the ESSDAI, and increase the reliability of rating and consequently of the ability to detect true changes over time. This better appraisal of ESSDAI items, along with the recent definition of disease activity levels and minimal clinically important change, will improve the assessment of patients with primary SS and facilitate the demonstration of effectiveness of treatment for patients with primary SS.

Published
2015

34. Reumatoid artrit

Author

Stengaard-Pedersen, Kristian, Østergaard, Mikkel, Hørslev-Petersen, Kim, Heller Asmussen, Karsten, Hetland, Merete Lund, Pødenphant, Claus Manniche, Jacobsen, Søren, Stengaard-Pedersen, Kristian, and Tarp Jacobsen, Johannes Friis

Published
2012

35. Sjögrens syndrom

Author

Pødenphant, Jan, Jacobsen, Søren, Manniche, Claus, Steengaard-Pedersen, Kristian, Tarp, Ulrik, Asmussen, Karsten, Holm, Lars Morten, Pedersen, Anne Marie Lynge, Pødenphant, Jan, Jacobsen, Søren, Manniche, Claus, Steengaard-Pedersen, Kristian, Tarp, Ulrik, Asmussen, Karsten, Holm, Lars Morten, and Pedersen, Anne Marie Lynge

Published
2012

38. Asmussen, Karsten

Author

Asmussen, Karsten and Asmussen, Karsten

Published
2011

39. MRI inflammation in the sacroiliac joints is associated with CTX-II and changes in systemic inflammation during TNFa inhibitor therapy.

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Lambert, Robert, Hermann, Kay-Geert, Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Hansen, Annette, Hansen, Michael Sejer, Thamsborg, Gorm Milan, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Østergaard, Mikkel, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Lambert, Robert, Hermann, Kay-Geert, Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Hansen, Annette, Hansen, Michael Sejer, Thamsborg, Gorm Milan, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, and Østergaard, Mikkel

Published
2010

40. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hermann, Kay-Geert A, Madsen, Ole Rintek, Tvede, Niels, Hansen, Michael Sejer, Thamsborg, Gorm, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten Heller, Johansen, Julia S, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Hansen, Annette, Østergaard, Mikkel, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hermann, Kay-Geert A, Madsen, Ole Rintek, Tvede, Niels, Hansen, Michael Sejer, Thamsborg, Gorm, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten Heller, Johansen, Julia S, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Hansen, Annette, and Østergaard, Mikkel

Abstract

To investigate construct validity and responsiveness of the novel ankylosing spondylitis (AS) disease activity score (ASDAS) in patients with spondyloarthritis (SpA).

Published
2010

41. The ankylosing spondylitis disease activity score (ADAS) better reflects the inflammatory disease processes than BASDAI. - A comparison with biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF-blockers.

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Garnero, P., Johansen, Julia Sidenius, Madsen, Ole Rintek, Tvede, Niels, Hansen, Mikael Secher, Thamsborg, Gorm Milan, Andersen, Lasse Darling, Majgaard, O., Loft, Anne Gitte, Erlendsson, J., Asmussen, Karsten Heller, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorte, Skjødt, Thomas, Hansen, Annette, Østergaard, Mikkel, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Garnero, P., Johansen, Julia Sidenius, Madsen, Ole Rintek, Tvede, Niels, Hansen, Mikael Secher, Thamsborg, Gorm Milan, Andersen, Lasse Darling, Majgaard, O., Loft, Anne Gitte, Erlendsson, J., Asmussen, Karsten Heller, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorte, Skjødt, Thomas, Hansen, Annette, and Østergaard, Mikkel

Published
2010

42. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with TNFa inhibitors

Author

Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hermann, Kay-Geert, Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Hansen, Annette, Hansen, Michael Sejer, Thamsborg, Gorm Milan, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, Østergaard, Mikkel, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hermann, Kay-Geert, Garnero, Patrick, Johansen, Julia Sidenius, Madsen, Ole Rintek, Hansen, Annette, Hansen, Michael Sejer, Thamsborg, Gorm Milan, Andersen, Lis Smedegaard, Majgaard, Ole, Loft, Anne Gitte, Erlendsson, Jon, Asmussen, Karsten, Jurik, Anne Grethe, Møller, Jakob Møllenbach, Hasselquist, Maria, Mikkelsen, Dorrit, Skjødt, Thomas, and Østergaard, Mikkel

Published
2010

44. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor α inhibitors

Author

Pedersen, Susanne Juhl, primary, Sørensen, Inge Juul, additional, Hermann, Kay-Geert A, additional, Madsen, Ole Rintek, additional, Tvede, Niels, additional, Hansen, Michael Sejer, additional, Thamsborg, Gorm, additional, Andersen, Lis Smedegaard, additional, Majgaard, Ole, additional, Loft, Anne Gitte, additional, Erlendsson, Jon, additional, Asmussen, Karsten, additional, Johansen, Julia S, additional, Jurik, Anne Grethe, additional, Møller, Jakob, additional, Hasselquist, Maria, additional, Mikkelsen, Dorrit, additional, Skjødt, Thomas, additional, Hansen, Annette, additional, and Østergaard, Mikkel, additional

Published
2009
Full Text
View/download PDF

45. Preface

Author

Manthorpe, Rolf, primary and Asmussen, Karsten, additional

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results